Session

Systemic treatment for advanced prostate and urothelial cancer

Thematic Session 15

  • Location:
    Room 14a (ICM, Level 1)
  • Chair:
     M. De Santis, Coventry (GB)
  • Aims and objectives of this session

    This session will give an overview of systemic treatments for bladder and prostate cancer including chemotherapy and immunotherapy. It will focus on controversies and new insights as well as the treatment of subgroups and rarer histologies.

State-of-the-art lecture Peri-operative chemotherapy for invasive bladder cancer: Oncological aspects
 C.N. Sternberg, Rome (IT)
State-of-the-art lecture Peri-operative chemotherapy for invasive bladder cancer: Urological aspects
 M. Retz, Munich (DE)
State-of-the-art lecture Immunotherapy for bladder cancer - benefit for all patients?
 I. Duran, Seville (ES)
Aims and objectives of this presentation

• To become familiar with basics principles of immunology
• To understand the rationale of harnessing the patient’s immune system as a therapeutic strategy in the treatment of bladder cancer
• To be up-to-date with the most recent data on immunotherapy in advanced urothelial cancer and current challenges in this setting with a special focus on patient’s selection and the current knowledge about biomarkers of response

State-of-the-art lecture Prostate cancer - Management of atypical histologies
 J.P. Bedke, Tübingen (DE)
State-of-the-art lecture Immunotherapy for prostate cancer: What the future holds
 P.F.A. Mulders, Nijmegen (NL)
Aims and objectives of this presentation

Prostate cancer was always considered as an immune indolent tumor, although in solid tumors the first effective vaccine approved was in prostate cancer. De immune response against prostate cancer cells can be enhanced by effective combinations of checkpoint inhibitors, specific proteins and antibodies. The future and implementations of these very promising treatment options will be discussed.

Questions and answers